Annual Report & Other Reports

Annual Report & Other Reports By Year: All | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018

17 Apr 2026 Sustainability Report FY2025
10 Apr 2026 Annual Report FY2025
09 Apr 2026 Evolve Capital’s Equity Research – No Clear Catalysts, FY26 Recovery a Low-Bar Normalisation
05 Mar 2026 PhillipCapital’s Equity Research – Hit the Refresh Button
03 Sep 2025 Evolve Capital’s Equity Research – 1H2025: Near Term Performance Likely to Remain Subdued Before Modest Recovery
25 Aug 2025 PhillipCapital’s Equity Research – 1H2025: Bump in the Road, Scaling Up Journey Intact
20 Aug 2025 CGS International’s Equity Research – 1H2025 In the Midst of Product Portfolio Review
11 Apr 2025 Annual Report FY2024
03 Apr 2025 Evolve Capital’s Equity Research – Initiating Coverage: Decent Fundamentals, Weak Valuations
10 Mar 2025 SAC Capital’s Equity Research – FY2024: Strong Growth Momentum
03 Mar 2025 CGS International’s Equity Research – Reinvesting for Growth in FY25F
13 Nov 2024 CGS International’s Equity Research – 3Q2024: Slowing Revenue Momentum
11 Sep 2024 CGS International Equity Research – 1H2024: Healthy Pipeline of New Products
22 Aug 2024 SAC Capital’s Equity Research – 1H2024: Commendable Growth Amid Economic Headwinds
21 Aug 2024 PhillipCapital’s Equity Research – 1H2024: New Products and Wider Distribution
16 May 2024 SAC Capital’s Equity Research – 1Q2024: Robust Growth Across All Segments
15 May 2024 CGS International’s Equity Research: Positive Revenue Momentum in 1Q24
09 Apr 2024 Annual Report FY2023
13 Mar 2024 CGS International’s Equity Research: FY2023 Positive on Expanding Portfolio
27 Nov 2023 CGS-CIMB’s Equity Research: Dented Margins in 3Q23
20 Nov 2023 SAC Capital’s Equity Research – 3Q23 Business Update
20 Oct 2023 SAC Capital’s Equity Research – Pursuing Growth Through Full Acquisition of Ardence Pharma
22 Aug 2023 PhillipCapital’s Equity Research – Year of Investment and Challenges
18 Aug 2023 Investor-One: What You Need to Know About Hyphens Pharma’s 1H2023 Financial Results
18 Aug 2023 CGS-CIMB’s Equity Research: A Game of Catch-Up for 2H23F
17 Aug 2023 SAC Capital’s Equity Research – Navigating Challenges Amidst Ongoing Improvements
25 May 2023 SAC Capital’s Equity Research – Beyond the Shores
16 May 2023 CGS-CIMB Singapore’s Equity Research – Hit by Supply Chain Disruptions
13 Apr 2023 CGS-CIMB Singapore’s Equity Research – DocMed Undertakes Vietnam Digital Venture
10 Apr 2023 Annual Report FY2022
09 Mar 2023 PhillipCapital’s Equity Research – Assembling Multiple Growth Engines
07 Mar 2023 CGS-CIMB Singapore’s Equity Research – FY23F Sets Stage for More Investments
24 Nov 2022 CGS-CIMB Singapore’s Equity Research – Steadfast in Executing its Business Strategy
28 Aug 2022 PhillipCapital’s Equity Research – Franchise Expands with Acquisitions
18 Aug 2022 SAC Capital’s Equity Research – Growth from Organic and Acquisition
17 Aug 2022 CGS-CIMB Singapore’s Equity Research – Positioning for Next Phase of Growth
06 Jun 2022 SAC Capital’s Equity Research – Receives S$6m Fund Infusion, Digital Assets Valued at S$60m
06 Jun 2022 PhillipCapital’s Equity Research – Digital Healthcare Catalyst Emerges
31 May 2022 Sustainability Report 2021
17 May 2022 SAC Capital’s Equity Research – Sterling 1Q22 Backed by Re-Opening Tailwind
13 May 2022 CGS-CIMB Singapore’s Equity Research – Building Up the Hype
12 Apr 2022 Annual Report 2021
04 Apr 2022 KGI Securities’ Equity Research – Novem Acquisition to Boost Top and Bottom-Line Growth
16 Mar 2022 SAC Capital’s Equity Research – Moving in the Right Direction
02 Mar 2022 CGS-CIMB Singapore’s Equity Research – Quality Earnings to Come in FY22F
06 Jan 2022 CGS-CIMB Singapore’s Equity Research – On the Lookout for Growth
22 Nov 2021 PhillipCapital’s Equity Research – Speedbump in Vietnam
18 Nov 2021 SAC Capital’s Equity Research – Strategic Acquisition of Novem Group
24 Aug 2021 SAC Capital’s Equity Research – Strongest 1H Recorded
28 Jun 2021 KGI Securities’ Equity Research – A Fresh Start
17 May 2021 Sustainability Report 2020
12 Apr 2021 Annual Report 2020
17 Mar 2021 SAC Capital’s Equity Research – Growing Regional Presence
05 Mar 2021 PhillipCapital’s Equity Research – Not to Be Written Off
19 Nov 2020 SAC Capital’s Equity Research – Q3 Setback, Longer-Term Growth is Priority
16 Nov 2020 KGI Securities’ Equity Research – Short Term Speed Bump in the Pursuit of Growth
16 Nov 2020 PhillipCapital’s Equity Research – Repositioning for Growth
06 Nov 2020 KGI Securities’ Equity Research – Skin is the game
29 Sep 2020 Lim & Tan Securities’ Equity Research – Special Report
31 Aug 2020 SAC Capital’s Equity Research – Broadening Product Range and Footprints
24 Aug 2020 KGI Securities’ Equity Research – A Hair-Raising First Half
20 Aug 2020 PhillipCapital’s Equity Research – Shaking Off COVID-19 Woes with Expanded Portfolio
20 Jul 2020 PhillipCapital’s Equity Research – Building Channels to Establish Business Longevity
26 May 2020 Sustainability Report 2019
15 May 2020 RHB’s Equity Research – Numbers Improve During Pandemic; Stay BUY
08 Apr 2020 Annual Report 2019
04 Mar 2020 RHB’s Equity Research – Near-Term Outlook Uncertain Due to COVID-19; BUY Maintained
22 Nov 2019 SAC Capital’s Equity Research – 3Q2019 Results Review
20 Nov 2019 RHB’s Equity Research – Banking on Ceradan Products; Keep Buy
08 Nov 2019 SAC Capital’s Equity Research – Healthy Prospects in ASEAN
22 Oct 2019 PhillipCapital’s Equity Research – Leveraging on Trust with Doctors for Profitability
20 Aug 2019 RHB’s Equity Research – Ceradan Leading The Pack; Keep Buy
03 Jul 2019 RHB’s Equity Research – Hyphens Pharma: Undervalued and Under-Covered; Initiate BUY
31 Dec 2018 Annual Report 2018
11 May 2018 IPO Offer Document
17 Apr 2026 Sustainability Report FY2025
10 Apr 2026 Annual Report FY2025
09 Apr 2026 Evolve Capital’s Equity Research – No Clear Catalysts, FY26 Recovery a Low-Bar Normalisation
05 Mar 2026 PhillipCapital’s Equity Research – Hit the Refresh Button
03 Sep 2025 Evolve Capital’s Equity Research – 1H2025: Near Term Performance Likely to Remain Subdued Before Modest Recovery
25 Aug 2025 PhillipCapital’s Equity Research – 1H2025: Bump in the Road, Scaling Up Journey Intact
20 Aug 2025 CGS International’s Equity Research – 1H2025 In the Midst of Product Portfolio Review
11 Apr 2025 Annual Report FY2024
03 Apr 2025 Evolve Capital’s Equity Research – Initiating Coverage: Decent Fundamentals, Weak Valuations
10 Mar 2025 SAC Capital’s Equity Research – FY2024: Strong Growth Momentum
03 Mar 2025 CGS International’s Equity Research – Reinvesting for Growth in FY25F
13 Nov 2024 CGS International’s Equity Research – 3Q2024: Slowing Revenue Momentum
11 Sep 2024 CGS International Equity Research – 1H2024: Healthy Pipeline of New Products
22 Aug 2024 SAC Capital’s Equity Research – 1H2024: Commendable Growth Amid Economic Headwinds
21 Aug 2024 PhillipCapital’s Equity Research – 1H2024: New Products and Wider Distribution
16 May 2024 SAC Capital’s Equity Research – 1Q2024: Robust Growth Across All Segments
15 May 2024 CGS International’s Equity Research: Positive Revenue Momentum in 1Q24
09 Apr 2024 Annual Report FY2023
13 Mar 2024 CGS International’s Equity Research: FY2023 Positive on Expanding Portfolio
27 Nov 2023 CGS-CIMB’s Equity Research: Dented Margins in 3Q23
20 Nov 2023 SAC Capital’s Equity Research – 3Q23 Business Update
20 Oct 2023 SAC Capital’s Equity Research – Pursuing Growth Through Full Acquisition of Ardence Pharma
22 Aug 2023 PhillipCapital’s Equity Research – Year of Investment and Challenges
18 Aug 2023 Investor-One: What You Need to Know About Hyphens Pharma’s 1H2023 Financial Results
18 Aug 2023 CGS-CIMB’s Equity Research: A Game of Catch-Up for 2H23F
17 Aug 2023 SAC Capital’s Equity Research – Navigating Challenges Amidst Ongoing Improvements
25 May 2023 SAC Capital’s Equity Research – Beyond the Shores
16 May 2023 CGS-CIMB Singapore’s Equity Research – Hit by Supply Chain Disruptions
13 Apr 2023 CGS-CIMB Singapore’s Equity Research – DocMed Undertakes Vietnam Digital Venture
10 Apr 2023 Annual Report FY2022
09 Mar 2023 PhillipCapital’s Equity Research – Assembling Multiple Growth Engines
07 Mar 2023 CGS-CIMB Singapore’s Equity Research – FY23F Sets Stage for More Investments
24 Nov 2022 CGS-CIMB Singapore’s Equity Research – Steadfast in Executing its Business Strategy
28 Aug 2022 PhillipCapital’s Equity Research – Franchise Expands with Acquisitions
18 Aug 2022 SAC Capital’s Equity Research – Growth from Organic and Acquisition
17 Aug 2022 CGS-CIMB Singapore’s Equity Research – Positioning for Next Phase of Growth
06 Jun 2022 SAC Capital’s Equity Research – Receives S$6m Fund Infusion, Digital Assets Valued at S$60m
06 Jun 2022 PhillipCapital’s Equity Research – Digital Healthcare Catalyst Emerges
31 May 2022 Sustainability Report 2021
17 May 2022 SAC Capital’s Equity Research – Sterling 1Q22 Backed by Re-Opening Tailwind
13 May 2022 CGS-CIMB Singapore’s Equity Research – Building Up the Hype
12 Apr 2022 Annual Report 2021
04 Apr 2022 KGI Securities’ Equity Research – Novem Acquisition to Boost Top and Bottom-Line Growth
16 Mar 2022 SAC Capital’s Equity Research – Moving in the Right Direction
02 Mar 2022 CGS-CIMB Singapore’s Equity Research – Quality Earnings to Come in FY22F
06 Jan 2022 CGS-CIMB Singapore’s Equity Research – On the Lookout for Growth
22 Nov 2021 PhillipCapital’s Equity Research – Speedbump in Vietnam
18 Nov 2021 SAC Capital’s Equity Research – Strategic Acquisition of Novem Group
24 Aug 2021 SAC Capital’s Equity Research – Strongest 1H Recorded
28 Jun 2021 KGI Securities’ Equity Research – A Fresh Start
17 May 2021 Sustainability Report 2020
12 Apr 2021 Annual Report 2020
17 Mar 2021 SAC Capital’s Equity Research – Growing Regional Presence
05 Mar 2021 PhillipCapital’s Equity Research – Not to Be Written Off
19 Nov 2020 SAC Capital’s Equity Research – Q3 Setback, Longer-Term Growth is Priority
16 Nov 2020 KGI Securities’ Equity Research – Short Term Speed Bump in the Pursuit of Growth
16 Nov 2020 PhillipCapital’s Equity Research – Repositioning for Growth
06 Nov 2020 KGI Securities’ Equity Research – Skin is the game
29 Sep 2020 Lim & Tan Securities’ Equity Research – Special Report
31 Aug 2020 SAC Capital’s Equity Research – Broadening Product Range and Footprints
24 Aug 2020 KGI Securities’ Equity Research – A Hair-Raising First Half
20 Aug 2020 PhillipCapital’s Equity Research – Shaking Off COVID-19 Woes with Expanded Portfolio
20 Jul 2020 PhillipCapital’s Equity Research – Building Channels to Establish Business Longevity
26 May 2020 Sustainability Report 2019
15 May 2020 RHB’s Equity Research – Numbers Improve During Pandemic; Stay BUY
08 Apr 2020 Annual Report 2019
04 Mar 2020 RHB’s Equity Research – Near-Term Outlook Uncertain Due to COVID-19; BUY Maintained
22 Nov 2019 SAC Capital’s Equity Research – 3Q2019 Results Review
20 Nov 2019 RHB’s Equity Research – Banking on Ceradan Products; Keep Buy
08 Nov 2019 SAC Capital’s Equity Research – Healthy Prospects in ASEAN
22 Oct 2019 PhillipCapital’s Equity Research – Leveraging on Trust with Doctors for Profitability
20 Aug 2019 RHB’s Equity Research – Ceradan Leading The Pack; Keep Buy
03 Jul 2019 RHB’s Equity Research – Hyphens Pharma: Undervalued and Under-Covered; Initiate BUY
31 Dec 2018 Annual Report 2018
11 May 2018 IPO Offer Document